Zacks: Analysts Expect Cocrystal Pharma, Inc. (NASDAQ:COCP) to Post -$0.04 EPS

Equities analysts expect that Cocrystal Pharma, Inc. (NASDAQ:COCPGet Rating) will report ($0.04) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Cocrystal Pharma’s earnings, with estimates ranging from ($0.04) to ($0.03). Cocrystal Pharma also reported earnings of ($0.04) per share during the same quarter last year. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Cocrystal Pharma will report full year earnings of ($0.15) per share for the current year. For the next year, analysts expect that the company will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.16) to ($0.14). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Cocrystal Pharma.

Cocrystal Pharma (NASDAQ:COCPGet Rating) last announced its quarterly earnings results on Wednesday, March 23rd. The company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04).

A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Cocrystal Pharma from a “sell” rating to a “hold” rating in a research report on Monday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Cocrystal Pharma in a research note on Monday, March 14th.

A number of institutional investors and hedge funds have recently made changes to their positions in COCP. Raymond James Financial Services Advisors Inc. increased its stake in Cocrystal Pharma by 108.7% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 24,243 shares of the company’s stock worth $25,000 after buying an additional 12,625 shares during the period. Barclays PLC increased its position in shares of Cocrystal Pharma by 248.5% in the 3rd quarter. Barclays PLC now owns 26,665 shares of the company’s stock valued at $28,000 after purchasing an additional 19,014 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Cocrystal Pharma by 5,155.0% in the 4th quarter. JPMorgan Chase & Co. now owns 59,959 shares of the company’s stock valued at $39,000 after purchasing an additional 58,818 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Cocrystal Pharma in the 3rd quarter valued at approximately $60,000. Finally, LPL Financial LLC increased its position in shares of Cocrystal Pharma by 12.2% in the 4th quarter. LPL Financial LLC now owns 200,250 shares of the company’s stock valued at $130,000 after purchasing an additional 21,750 shares during the last quarter. 16.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of COCP opened at $0.52 on Friday. Cocrystal Pharma has a 1-year low of $0.45 and a 1-year high of $3.46. The stock has a market cap of $50.59 million, a PE ratio of -3.24 and a beta of 1.09. The firm has a 50-day simple moving average of $0.54 and a two-hundred day simple moving average of $0.68.

Cocrystal Pharma Company Profile (Get Rating)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

Featured Stories

Get a free copy of the Zacks research report on Cocrystal Pharma (COCP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.